TAXANES - A NEW CLASS OF ANTITUMOR AGENTS

被引：244
作者：
HUIZING, MT
MISSER, VHS
PIETERS, RC
HUININK, WWT
VEENHOF, CHN
VERMORKEN, JB
PINEDO, HM
BEIJNEN, JH
机构：
[1] SLOTERVAART HOSP,DEPT PHARM,1066 EC AMSTERDAM,NETHERLANDS
[2] NETHERLANDS CANC INST,DEPT MED ONCOL,1066 CX AMSTERDAM,NETHERLANDS
[3] UNIV AMSTERDAM,ACAD MED CTR,DEPT MED ONCOL,1105 AZ AMSTERDAM,NETHERLANDS
[4] FREE UNIV AMSTERDAM HOSP,DEPT MED ONCOL,1081 HV AMSTERDAM,NETHERLANDS
来源：
CANCER INVESTIGATION | 1995年 / 13卷 / 04期
关键词：
D O I：
10.3109/07357909509031919
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Taxanes belong to a new group of antineoplastic agents with a novel mechanism of action for a cytotoxic drug. They promote microtubule assembly and stabilize the microtubules. Paclitaxel, the first agent in this group to become available, was isolated from the Pacific yew, Taxus brevifolia, in 1971. In preclinical and clinical studies, paclitaxel and its semisynthetic analog docetaxel exhibit significant antitumor activity. This review deals with the physicochemical properties, pharmacology, and results of preclinical and clinical trials of the taxanes.
引用
收藏
页码：381 / 404
页数：24
相关论文
共 173 条
[1]  
AAPRO M, 1993, P AM SOC CLIN ONCOL, V12, P809
[2]  
ARBUCK S, 1993, P AM SOC CLIN ONCOL, V12, P350
[3]   THE ABSENCE OF CUMULATIVE BONE-MARROW TOXICITY IN PATIENTS WITH RECURRENT ADENOCARCINOMA OF THE OVARY RECEIVING DOSE-INTENSE TAXOL AND GRANULOCYTE-COLONY STIMULATING FACTOR [J].
BICHER, A ;
KOHN, E ;
SAROSY, G ;
DAVIS, P ;
ADAMO, DO ;
JACOB, J ;
CHRISTIAN, M ;
REED, E .
ANTI-CANCER DRUGS, 1993, 4 (02) :141-148
[4]  
BISSERY MC, 1991, CANCER RES, V51, P4845
[5]  
BISSERY MC, 1990, P AACR, V31, P2475
[6]  
BISSERY MC, 1993, P AM ASSOC CANC RES, V34, P1782
[7]  
BISSETT D, 1993, CANCER RES, V53, P523
[8]  
BRANDWEIN MS, 1988, MT SINAI J MED, V55, P187
[9]   A PHASE-I TRIAL OF TAXOL GIVEN BY A 6-HOUR INTRAVENOUS-INFUSION [J].
BROWN, T ;
HAVLIN, K ;
WEISS, G ;
CAGNOLA, J ;
KOELLER, J ;
KUHN, J ;
RIZZO, J ;
CRAIG, J ;
PHILLIPS, J ;
VONHOFF, D .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (07) :1261-1267
[10]   PHASE-I CLINICAL-TRIAL OF TAXOTERE ADMINISTERED AS EITHER A 2-HOUR OR 6-HOUR INTRAVENOUS-INFUSION [J].
BURRIS, H ;
IRVIN, R ;
KUHN, J ;
KALTER, S ;
SMITH, L ;
SHAFFER, D ;
FIELDS, S ;
WEISS, G ;
ECKARDT, J ;
RODRIGUEZ, G ;
RINALDI, D ;
WALL, J ;
COOK, G ;
SMITH, S ;
VREELAND, F ;
BAYSSAS, M ;
LEBAIL, N ;
VONHOFF, D .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (05) :950-958
12345678910